OCM
LGND icon

One Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

One Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76M Hold
13,847
– – 0.08% 174
2026
Q1 		$2.76M Buy
13,847
+4,560
+49% +$902K 0.08% 174
2025
Q4 		$1.76M Buy
+9,287
New +$1.78M 0.05% 224

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

One Capital Management's LGND Position: Q2 2026 in Review

One Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 13,847 shares worth $2.76M. The position accounts for 0.08% of the portfolio, ranked #174.

One Capital Management first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • One Capital Management held 13,847 shares of Ligand Pharmaceuticals worth $2.76M as of Q2 2026.
  • One Capital Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 0.08% of One Capital Management's portfolio in Q2 2026, its #174 holding.
  • One Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on One Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.